David R Spigel, MD
SCRI Development Innovations, LLC · Sarah Cannon, The Cancer Institute of HCA Healthcare · Sarah Cannon Research Insititute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David R Spigel, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02087176 · A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung CancerAstraZeneca · terminated · Previously Treated Non Small Cell Lung Cancer · study chair
- Ph2NCT02087241 · Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung CancerAstraZeneca · terminated · Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer · principal investigator
- N/ANCT01817192 · Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)Razor Genomics · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- N/ANCT01522833 · Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or LongerSCRI Development Innovations, LLC · completed · Non Small Cell Lung Cancer · study chair
- Ph2NCT01487265 · Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibSCRI Development Innovations, LLC · completed · Non Small Cell Lung Cancer · study chair
- Ph2NCT01042288 · Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLCSCRI Development Innovations, LLC · completed · Non-Small-Cell Lung Cancer · study chair
- Ph2NCT00951613 · A Study of NK012 in Patients With Relapsed Small Cell Lung CancerNippon Kayaku Co., Ltd. · completed · Small Cell Lung Cancer · principal investigator
- Ph2NCT00741988 · Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerSCRI Development Innovations, LLC · completed · Non-Small Cell Lung Cancer · study chair
- Ph2NCT00456261 · First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCSCRI Development Innovations, LLC · completed · Lung Cancer · principal investigator
- Ph2NCT00308516 · 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal CancerSCRI Development Innovations, LLC · completed · Rectal Cancer, Cancer of the Rectum, Colorectal Cancer · principal investigator
- Ph2NCT00308529 · Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Carcinoma, Small Cell Lung, Lung Cancer · principal investigator
- Ph2NCT00305942 · Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Carcinoma, Small Cell · principal investigator
- Ph2NCT00294931 · Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Carcinoma, Small Cell Lung · principal investigator
- Ph2NCT00294190 · Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung CancerSCRI Development Innovations, LLC · completed · Small Cell Lung Cancer, Carcinoma, Small Cell · principal investigator
- Ph2NCT00284154 · Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Carcinoma, Small Cell, Lung Cancer · principal investigator
- Ph1/Ph2NCT00193128 · Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus CancerSCRI Development Innovations, LLC · completed · Esophagus Cancer · principal investigator
- Ph2NCT00193219 · Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal CancerSCRI Development Innovations, LLC · completed · Colon Cancer · principal investigator
- Ph2NCT00193414 · Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Lung Cancer · principal investigator
- Ph2NCT00193427 · Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Lung Cancer · principal investigator
- Ph2NCT00193453 · Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerSCRI Development Innovations, LLC · completed · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.